Ralf Hofheinz
Overview
Explore the profile of Ralf Hofheinz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hofheinz R, Lorenzen S, Bohlmann M
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444443
Almost 25 years ago, trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), was licensed for the treatment of patients with metastatic HER2-positive breast cancer in...
2.
Lordick F, Lorenzen S, Hofheinz R
Oncol Res Treat
. 2023 Feb;
46(9):345-347.
PMID: 36780881
No abstract available.
3.
Ebert M, Meindl-Beinker N, Gutting T, Maenz M, Betge J, Schulte N, et al.
Lancet Healthy Longev
. 2022 Sep;
3(6):e417-e427.
PMID: 36098320
Background: The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival...
4.
Ghadimi M, Rodel C, Hofheinz R, Flebbe H, Grade M
Dtsch Arztebl Int
. 2022 Jul;
119(33-34):570-580.
PMID: 35791271
Background: Colorectal cancer is one of the three most common types of cancer in Germany. Approximately 30% of these cancers are located in the rectum, corresponding to about 18 000...
5.
Hohneck A, Custodis F, Rosenkaimer S, Hofheinz R, Maier S, Akin I, et al.
Eur J Public Health
. 2021 Sep;
31(6):1170-1176.
PMID: 34516614
Background: Cardiooncology is a relatively new subspeciality, investigating the side effects of cytoreductive therapies on the cardiovascular (CV) system. Gender differences are well known in oncological and CV diseases, but...
6.
Hohneck A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, Hofheinz R, Boda-Heggemann J, et al.
Anticancer Res
. 2020 Jul;
40(7):4137-4145.
PMID: 32620663
Background/aim: Lung diseases are common in patients with abdominal aortic aneurysms (AAA). This study evaluates the prevalence of lung cancer (LC) in high-risk patients screened for AAA. Patients And Methods:...
7.
Hartmann J, Kopp H, Gruenwald V, Piperno-Neumann S, Kunitz A, Hofheinz R, et al.
Eur J Cancer
. 2019 Dec;
124:152-160.
PMID: 31785463
Doxorubicin represents the standard first-line treatment for metastatic soft-tissue sarcoma. We assessed the efficacy and safety of trofosfamide in elderly patients. In this controlled phase II trial, we randomly (1:2)...
8.
Krug D, Hofheinz R, Gkika E, Brunner T, Boda-Heggemann J
Strahlenther Onkol
. 2019 Nov;
196(1):98-100.
PMID: 31732781
No abstract available.
9.
Ronellenfitsch U, Jensen K, Seide S, Kieser M, Schwarzbach M, Slanger T, et al.
Eur J Cancer
. 2019 Nov;
123:101-111.
PMID: 31678767
Introduction: Disease-free survival (DFS) is increasingly being used as surrogate end-point for overall survival (OS) in cancer trials. So far, there has been no validation of the surrogacy of DFS...
10.
Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, et al.
Oncology
. 2019 Sep;
98(1):16-22.
PMID: 31514200
Purpose: Preclinical studies indicated that imatinib may have single-agent activity in glioblastoma through inhibition of tyrosine kinase activity and also that it might enhance the efficacy of radiotherapy. We therefore...